Possis Medical gets $17 million financing:
This article was originally published in Clinica
Possis Medical has secured a financing commitment for up to $17 million from a group of institutional investors. The Minneapolis-based company will use the proceeds for research and development into applications for its AngioJet Rheolytic Thrombectomy system - which is sold in the US for the treatment of dialysis access graft thrombosis - as well as expanding its sales and marketing operations. The company says the AngioJet system can be used to quickly remove blood clots from vessels. It has been designed to treat a range of conditions, including heart attacks, stroke, dialysis access failure, pulmonary embolism and deep vein thrombosis.